Business Context and Reporting Period
Company: Rand Capital Corporation (Rand), a publicly traded Business Development Company (BDC) and its wholly-owned subsidiary, Rand Capital SBIC, Inc. (Rand SBIC), a Small Business Investment Company (SBIC).
Reporting Period: Quarterly Report (Form 10-Q) for the period ended June 30, 2014.
Business Overview: Rand invests in small to medium-sized companies through a mix of debt and equity instruments. The portfolio is heavily weighted toward private, restricted securities (97% of fair value), with a focus on manufacturing, software, and healthcare sectors.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2014 | Six Months Ended June 30, 2013 |
|---|---|---|
| Total Investment Income | $1,189,506 | $1,502,604 |
| Total Expenses | $756,320 | $676,264 |
| Net Investment Gain | $335,343 | $543,224 |
| Net Realized (Loss) Gain | ($802,966) | $487,467 |
| Net Unrealized Appreciation | $817,786 | ($952,684) |
| Net Increase in Net Assets from Operations | $350,163 | $78,007 |
| Cash and Cash Equivalents | $4,090,943 | $3,770,042 |
| Total Assets | $37,748,792 | $39,750,370 |
| Net Assets (Stockholders' Equity) | $28,419,415 | $25,521,216 |
| Net Asset Value (NAV) per Share | $4.43 | $3.90 (Year End 2013) |
| Debt (SBA Debentures) | $7,000,000 | $7,000,000 |
Material Changes vs. Prior Period
- Investment Portfolio Growth: Total investments at fair value increased by 17.3% to $33.25 million, driven by new investments totaling $4.5 million in companies such as Teleservices Solutions Holdings, SocialFlow, and Empire Genomics.
- Realized Losses: The company reported a net realized loss of $802,966 for the six months ended June 30, 2014, compared to a gain of $487,467 in the prior year. This was primarily due to a $778,253 realized loss on the sale of EmergingMed.com, Inc. and a $476,334 adjustment to the Liazon Corporation escrow receivable.
- Unrealized Appreciation: Net unrealized appreciation increased by $817,786, reversing a decrease in the prior year. Significant contributors included a $1.2 million write-up of BinOptics Corporation and a reclassification of the EmergingMed loss.
- Operating Expenses: Total expenses rose 11.8% to $756,320. This increase was partially offset by a $45,635 reduction in bonus/profit sharing expense due to an adjustment in the Liazon escrow receivable. However, interest expense on SBA obligations increased by 32% due to higher leverage levels ($7M vs $4M in 2013).
- Liquidity: Cash and cash equivalents decreased from $9.76 million at year-end 2013 to $4.09 million at June 30, 2014, reflecting active deployment of capital into new investments.
Outlook, Risks, and Management Commentary
- Outlook: Management anticipates that most future investments will be originated through the SBIC subsidiary. They expect current cash balances, combined with $1 million of available SBA leverage and portfolio distributions, to be sufficient for operations over the next 12 months.
- Valuation Risks: 97% of the portfolio consists of Level 3 assets (restricted securities) valued using unobservable inputs. Management notes that these fair values may differ significantly from amounts realized upon liquidation.
- Concentration Risk: Five portfolio companies (Gemcor II, BinOptics, Rheonix, Microcision, and Carolina Skiff) represented 58% of the total fair value of the investment portfolio as of June 30, 2014.
- Market Risk: The company is exposed to fluctuations in the value of publicly traded securities (e.g., Synacor) and the financial performance of private portfolio companies. Quarterly results may fluctuate significantly due to the timing of realized gains/losses.
- Share Repurchases: The Board authorized the repurchase of up to 1,000,000 shares through October 2014. Only 26 shares were repurchased in the first half of 2014.
Investor Verification Checklist
- Valuation Methodology: Verify the assumptions used for Level 3 asset valuations, particularly the $1.2 million write-up of BinOptics and the write-down of Knoa Software and Mezmeriz.
- Realized Loss Details: Review the specific circumstances surrounding the $778,253 loss on EmergingMed and the $476,334 adjustment to Liazon Corporation to assess future credit risk.
- Liquidity Position: Monitor the cash burn rate given the significant deployment of capital ($4.5M in new investments) and the reduction in cash reserves from $9.76M to $4.09M.
- Debt Obligations: Confirm the maturity schedule of the $7 million SBA debentures (maturing 2022-2024) and the impact of rising interest rates on future expense ratios.
- Portfolio Concentration: Assess the financial health of the top five portfolio holdings, which comprise the majority of the portfolio's fair value.